Kun Lee Email and Phone Number

Currently serving as Global Commercial Lead for epcoritamab (ph2/3 CD3-CD20 bispecific in NHL) in Hematological Malignancies

Served as Global Commercial Lead for telisotuzumab vedotin (ph2/3 biomarker-directed ADC in NSCLC) and biomarker/CDx strategies for Oncology portfolio

Global Head of CDx Commercialization for all Oncology assets in clinical pipeline, including near-term launch products

Served as Global Marketing Lead for SCLC strategic planning for Opdivo/Yervoy

Worldwide Oncology Commercial Development & Strategic Evaluation• Served as the Global Commercial Leader for Companion Diganostic (CDx) development & commercialization for Xalkori (crizotinib) and dacomitinib, as well as for pan-OBU CDx projects.• Led worldwide commercial development efforts to develop/implement Xalkori (crizotinib) strategies and tactics in preparation for global launches.• Spearheaded licensing and development valuations and commercial opportunity assessments for external pipeline and marketed oncology assets as commercial team leader.• Planned and executed commercial strategy for oncology programs in early development.• Performed commercial evaluations of biotechnology and pharmaceutical companies with oncology portfolios to support merger and acquisition activities. • Led a Tumor Strategy Team comprised of cross-functional members to assist Pfizer’s Oncology franchise better understand the value of hematological malignancies, and identify commercially viable fast-to-patient as well as longer-term opportunities. • Developed commercial guidance for discovery programs and implemented full development strategy for clinical compounds.

Biotech/Pharmaceutical Brand Marketing & Management Consulting• Managed and successfully executed US and EU launches for multi-million, -billion dollar projected products in the oncology, GI, CNS, immunology, and other TAs across multiple indications for the world’s top two largest biotechnology companies and several leading multi-national pharmaceutical manufacturers• Developed comprehensive commercialization plans for oncology, CV, CNS, immunology, and infectious disease products developed by top biotech companies and several of the “top ten” pharmaceutical companies; developed patient flow and customer segmentation models, conducted competitive and market assessments, hypothesized target product profiles, determined optimal product positioning and pricing, and developed high-level go-to-market strategies• Created interactive patient flow models for pharmaceutical/biotech clients to elucidate key market dynamics and isolate the value of individual target market segments

Pharmaceutical/Biotech Management Consulting• Designed the foundation and process with respect to the creation and management of an “established” brands portfolio and defined transition strategies for potential candidate products across several therapeutic areas.• Spearheaded a benchmarking initiative with “best-in-class” consumer marketing companies in order to 1) gain key insights, strategies, and tactics around leading consumer marketing capabilities and to 2) initiate the creation of a Center of Consumer Marketing Excellence at a top multi-national pharmaceutical company.• Managed two of the pilots in the cardiovascular and oncology therapeutic areas with a focus on driving consumers and patients through the “loyalty continuum” by selectively targeting qualified candidates to 1) increase compliance and persistency and 2) ultimately generate patient loyalty to our brands (included the establishment of ROI metrics).